Detalhe da pesquisa
1.
Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
N Engl J Med
; 384(7): 630-642, 2021 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33596357
2.
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
Hum Reprod
; 39(3): 526-537, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38243752
3.
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Lancet
; 399(10343): 2267-2279, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717987
4.
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
Am J Kidney Dis
; 61(4): 579-87, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23352379
5.
Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
F S Rep
; 4(2 Suppl): 73-82, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37223761
6.
A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.
Pain Manag
; 13(4): 205-211, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183454
7.
A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis.
Pain Manag
; 13(11): 631-640, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37982388
8.
Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.
Pain
; 159(5): 987-994, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29419653